BMJ:小剂量药物相比,小梁切除术具有相似的生活质量和安全性,且眼压更低。

2021-05-13 梅斯医学 MedSci原创

小剂量药物相比,小梁切除术具有相似的生活质量和安全性,并且眼压更低。

青光眼是一种慢性进行性眼病,对日常生活的许多方面都有实质性的不利影响。

开角型青光眼最初会影响周围的视力。晚期开角型青光眼患者会出现严重的视野缺失,侵占中心视力,最终降低视力。视野严重受限会降低生活质量,增加跌倒和骨折的风险。双眼都患有晚期开角型青光眼的人,即使视力良好,也可能有资格被认证为严重视力障碍。

有效的治疗可以控制疾病,防止视力进一步下降,从而防止失明。降低眼压是最有效的青光眼治疗方法。在诊断后的初始阶段更好地控制眼压可以减少进一步发展的风险。

Pixabay

近日,英国爱丁堡大学研究团队发表在BMJ上的研究显示,小剂量药物相比,小梁切除术具有相似的生活质量和安全性,并且眼压更低。

该研究在英国27个眼科中心进行,453位参与者在2014年6月3日至2017年5月31日期间至少一只眼睛出现了新诊断的晚期开角型青光眼(Hodapp分类)。

主要结果是在24个月时使用视觉功能问卷(VFQ-25)测量的健康相关生活质量。次要结局包括患者报告的结局:EuroQol Group的5维5级健康状况问卷(EQ-5D-5L),健康效用指数标记(HUI-3),青光眼效用指数(GUI),30和病人的经历。

对于VFQ-25,值的范围是从0(代表最低的视觉生活质量)到100(代表最高的视觉生活质量)。对于EQ-5D和HUI-3,得分0等于死亡状态,而1是完全健康状态。对于GUI,就青光眼的影响和治疗的副作用而言,0是最差的状态,而1则是可能的最佳状态。

次要临床疗效结果是眼压,平均分辨力对数(logMAR)视力对数,使用汉弗莱视野分析仪测量的视野平均偏差,白内障手术的需要,驾驶视觉标准的通过/不通过(基于(Esterman视野),视力障碍认证的资格以及干预措施的安全性。

研究分析发现,在24个月时,小梁切除术和医疗管理部门的VFQ-25平均得分分别为85.4(13.8)和84.5(16.3),平均差异为1.06(95%置信区间-1.32至3.43; P = 0.38)。

视觉功能问卷 

小梁切除术组在24个月时的平均眼内压为12.4mm Hg,医疗管理组为15.1mm Hg(平均差-2.75(95%置信区间-3.84至-1.66)mm Hg; P <0.001)。小梁切除术组的logMAR视敏度更高(更差)(平均差异0.07,0.02至0.11; P = 0.006)。且没有发现在24个月时视野平均偏差(平均差异0.18(-0.58至0.94)dB; P = 0.65)或其他次要结局差异的证据。

按组别划分的索引眼的平均眼压(IOP)随时间变化情况

研究结果表明,与小剂量药物相比,小梁切除术具有相似的生活质量和安全性,并且眼压更低。

原始出处:

Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS). BMJ 2021; 373 doi: https://doi.org/10.1136/bmj.n1014

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2027791, encodeId=2b7d202e7915f, content=<a href='/topic/show?id=ed424e041ad' target=_blank style='color:#2F92EE;'>#小梁切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47041, encryptionId=ed424e041ad, topicName=小梁切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri May 21 07:37:26 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014231, encodeId=944310142310f, content=视觉功能问卷, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62ea5443604, createdName=ms1000002128428491, createdTime=Fri Sep 03 10:05:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849255, encodeId=6bbd184925577, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Apr 15 20:37:26 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043620, encodeId=3b4420436204f, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jun 02 06:37:26 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877422, encodeId=831018e7422ba, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Dec 05 22:37:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294013, encodeId=d971129401365, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sat May 15 08:37:26 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2027791, encodeId=2b7d202e7915f, content=<a href='/topic/show?id=ed424e041ad' target=_blank style='color:#2F92EE;'>#小梁切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47041, encryptionId=ed424e041ad, topicName=小梁切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri May 21 07:37:26 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014231, encodeId=944310142310f, content=视觉功能问卷, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62ea5443604, createdName=ms1000002128428491, createdTime=Fri Sep 03 10:05:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849255, encodeId=6bbd184925577, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Apr 15 20:37:26 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043620, encodeId=3b4420436204f, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jun 02 06:37:26 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877422, encodeId=831018e7422ba, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Dec 05 22:37:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294013, encodeId=d971129401365, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sat May 15 08:37:26 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-09-03 ms1000002128428491

    视觉功能问卷

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2027791, encodeId=2b7d202e7915f, content=<a href='/topic/show?id=ed424e041ad' target=_blank style='color:#2F92EE;'>#小梁切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47041, encryptionId=ed424e041ad, topicName=小梁切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri May 21 07:37:26 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014231, encodeId=944310142310f, content=视觉功能问卷, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62ea5443604, createdName=ms1000002128428491, createdTime=Fri Sep 03 10:05:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849255, encodeId=6bbd184925577, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Apr 15 20:37:26 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043620, encodeId=3b4420436204f, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jun 02 06:37:26 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877422, encodeId=831018e7422ba, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Dec 05 22:37:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294013, encodeId=d971129401365, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sat May 15 08:37:26 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2022-04-15 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=2027791, encodeId=2b7d202e7915f, content=<a href='/topic/show?id=ed424e041ad' target=_blank style='color:#2F92EE;'>#小梁切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47041, encryptionId=ed424e041ad, topicName=小梁切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri May 21 07:37:26 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014231, encodeId=944310142310f, content=视觉功能问卷, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62ea5443604, createdName=ms1000002128428491, createdTime=Fri Sep 03 10:05:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849255, encodeId=6bbd184925577, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Apr 15 20:37:26 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043620, encodeId=3b4420436204f, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jun 02 06:37:26 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877422, encodeId=831018e7422ba, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Dec 05 22:37:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294013, encodeId=d971129401365, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sat May 15 08:37:26 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-06-02 pyaili
  5. [GetPortalCommentsPageByObjectIdResponse(id=2027791, encodeId=2b7d202e7915f, content=<a href='/topic/show?id=ed424e041ad' target=_blank style='color:#2F92EE;'>#小梁切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47041, encryptionId=ed424e041ad, topicName=小梁切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri May 21 07:37:26 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014231, encodeId=944310142310f, content=视觉功能问卷, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62ea5443604, createdName=ms1000002128428491, createdTime=Fri Sep 03 10:05:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849255, encodeId=6bbd184925577, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Apr 15 20:37:26 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043620, encodeId=3b4420436204f, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jun 02 06:37:26 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877422, encodeId=831018e7422ba, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Dec 05 22:37:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294013, encodeId=d971129401365, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sat May 15 08:37:26 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2027791, encodeId=2b7d202e7915f, content=<a href='/topic/show?id=ed424e041ad' target=_blank style='color:#2F92EE;'>#小梁切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47041, encryptionId=ed424e041ad, topicName=小梁切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri May 21 07:37:26 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014231, encodeId=944310142310f, content=视觉功能问卷, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62ea5443604, createdName=ms1000002128428491, createdTime=Fri Sep 03 10:05:15 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849255, encodeId=6bbd184925577, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Fri Apr 15 20:37:26 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043620, encodeId=3b4420436204f, content=<a href='/topic/show?id=a9c2469e327' target=_blank style='color:#2F92EE;'>#小剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46973, encryptionId=a9c2469e327, topicName=小剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jun 02 06:37:26 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877422, encodeId=831018e7422ba, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Dec 05 22:37:26 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294013, encodeId=d971129401365, content=<a href='/topic/show?id=6c20e273679' target=_blank style='color:#2F92EE;'>#眼压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72736, encryptionId=6c20e273679, topicName=眼压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Sat May 15 08:37:26 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-05-15 swallow

相关资讯

PLOS GENET:青光眼背后的遗传机制被发现了

目前估计全球有50%的青光眼失明是由原发性闭角型青光眼(PACG)引起的,但其致病基因尚不清楚。

Nature封面:重编程技术逆转视神经衰老时钟

异位表达的重编程转录因子在小鼠视网膜神经节细胞恢复了年轻的DNA甲基化模式和转录组,促进损伤后轴突再生,并扭转青光眼小鼠模型和老年小鼠的视力损失。

患青光眼会不会瞎?专家说虽不可逆却可控

今年3月7日~13日是第14个世界青光眼周,主题是“视野不丢,生活无忧”。3月10日,中山大学中山眼科中心举办科普活动。

从儿童近视到糖尿病视网膜病变,你需要知道多少?|2019CCOS

2019全国眼科学术大会热点话题,小M带你抢先看!

FDA批准Allergan的生物可降解植入药物Durysta,用于降低青光眼患者的眼内压

Allergan的可植入药物Durysta已获得美国食品和药物管理局(FDA)的批准,用于降低开角型青光眼或高眼压患者的眼压(IOP)。

Cell Death Dis:Alcα缺失可导致视网膜神经节细胞损伤

青光眼的发生涉及视网膜神经节细胞(RGC)的轴突病变,在老年人及眼内压升高(IOP)人群中更为常见。但在部分IOP正常或已通过药物控制的患者中也同样会出现青光眼表型。

拓展阅读

J Glaucoma:视神经鞘开窗术可以有效治疗小梁切除术后出现的视神经乳头水肿

华盛顿大学眼科学系的Radke PM近日在J Glaucoma发表了一篇文章,他们采用视神经鞘开窗手术可以有效治疗小梁切除术后出现的视神经乳头水肿症状。

North Clin Istanb:小梁切除术对开角型青光眼患者的眼高阶像差的影响

伊斯坦布尔大不列颠医科大学眼科的Fard AM近日在North Clin Istanb发表了一篇文章,评估小梁切除术对开角型青光眼患者术后眼高阶像差的影响。

Adv Ther:白内障超声乳化术对小梁切除术后高眼压患者眼压的影响!

意大利布雷西亚布雷西亚大学医学和外科专业的Quaranta L近日在Adv Ther杂志上发表了他们的一项新的工作,他们在低眼压黄斑病变患者中,经过白内障摘除手术和小梁切除术后,评估这些患者的视力变化。

关注青光眼围手术期的处理

即使在现代化的显微手术条件下,抗青光眼手术的并发症仍时有发生。仅就经典的小梁切除术而言,相关并发症的发生率高达20%左右。要做到青光眼手术的低并发症和高成功率并非易事! ·术前的全面评价和充分准备是减少青光眼手术并发症的关键。 ·熟悉患眼局部解剖和合理用药是青光眼围手术期处理的基本内容。 临床眼科医师实施青光眼手术前,必须熟悉患眼的角巩膜缘局部解剖结构,即活体外观前部半透明区(约1mm宽)